Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors

Trial Profile

A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Eribulin (Primary) ; Irinotecan (Primary)
  • Indications Ewing's sarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 07 Sep 2018 Planned End Date changed from 31 Oct 2020 to 30 Jun 2021.
    • 07 Sep 2018 Planned primary completion date changed from 30 Jun 2020 to 30 Jun 2021.
    • 15 Jun 2018 Planned number of patients changed from 86 to 111.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top